Ipsen (FR:IPN)
:IPN
Top Page
Ipsen
(IPN)
Select Model
Select Model
Rating:67Neutral
Price Target:
€171.00
▲(8.43% Upside)
Action:DowngradedDate:02/23/26
The score is driven by solid underlying financial performance (growth with still-healthy profitability and manageable leverage), supported by a strong uptrend in price. These positives are tempered by stretched technical momentum (RSI/Stoch elevated), margin compression and higher debt in 2025, and a relatively high P/E with a low dividend yield.
Positive Factors
Specialty biopharma portfolio
Ipsen's targeted specialty portfolio (oncology, neurology, rare diseases) and established brands such as Somatuline and Dysport create durable therapeutic demand, higher barriers to generic competition and steady commercial channels, supporting repeatable revenue and strategic R&D focus.
Negative Factors
Margin compression since 2021–2023
Meaningful decline in net margins versus prior years implies rising costs or adverse product mix, which reduces the firm's ability to convert revenue into sustainable profits. If structural, this pressures free cash flow, limits reinvestment capacity and can weaken long-term return on capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialty biopharma portfolio
Ipsen's targeted specialty portfolio (oncology, neurology, rare diseases) and established brands such as Somatuline and Dysport create durable therapeutic demand, higher barriers to generic competition and steady commercial channels, supporting repeatable revenue and strategic R&D focus.
Read all positive factors
Ipsen (IPN) vs. iShares MSCI France ETF (EWQ)
Market Cap
€13.04B
Dividend Yield1.17%
Average Volume (3M)64.26K
Price to Earnings (P/E)22.4
Beta (1Y)0.56
Revenue Growth9.57%
EPS Growth-34.30%
CountryFR
Employees5,358
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)6.02
Shares Outstanding83,814,530
10 Day Avg. Volume52,964
30 Day Avg. Volume64,259
Financial Highlights & Ratios
PEG Ratio0.82
Price to Book (P/B)2.29
Price to Sales (P/S)2.70
P/FCF Ratio9.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€138.50Price Target Upside-12.18% Downside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)12.25
Revenue Forecast (FY)€4.13B
Ipsen Business Overview & Revenue Model
Company Description
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegal...
How the Company Makes Money
Ipsen generates revenue primarily through the sale of its pharmaceutical products, which are marketed globally across various therapeutic areas. The company earns money from direct sales of its proprietary medications to healthcare providers and h...
Ipsen Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
78
Positive
Cash Flow
67
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.68B | 3.57B | 3.31B | 3.16B | 2.75B |
| Gross Profit | 2.59B | 2.96B | 2.74B | 2.63B | 2.31B |
| EBITDA | 1.10B | 1.16B | 1.14B | 1.13B | 1.06B |
| Net Income | 444.50M | 345.90M | 644.40M | 648.60M | 646.60M |
Balance Sheet | |||||
| Total Assets | 6.94B | 6.44B | 6.32B | 5.61B | 4.99B |
| Cash, Cash Equivalents and Short-Term Investments | 1.53B | 679.20M | 528.40M | 1.17B | 814.70M |
| Total Debt | 1.05B | 426.80M | 306.10M | 771.60M | 786.60M |
| Total Liabilities | 2.60B | 2.26B | 2.50B | 2.27B | 2.25B |
| Stockholders Equity | 4.34B | 4.18B | 3.83B | 3.34B | 2.74B |
Cash Flow | |||||
| Free Cash Flow | 1.03B | 133.00M | 749.70M | 700.30M | 453.90M |
| Operating Cash Flow | 1.14B | 915.50M | 865.90M | 953.20M | 871.80M |
| Investing Cash Flow | -615.20M | -676.60M | -1.07B | -458.60M | -332.00M |
| Financing Cash Flow | 298.40M | -100.00M | -458.40M | -146.00M | -400.30M |
Ipsen Technical Analysis
Positive
157.70
Price Trends
149.25
Positive
136.87
Positive
124.50
Positive
Market Momentum
0.44
Positive
57.68
Neutral
65.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:IPN, the sentiment is Positive. The current price of 157.7 is above the 20-day moving average (MA) of 155.77, above the 50-day MA of 149.25, and above the 200-day MA of 124.50, indicating a bullish trend. The MACD of 0.44 indicates Positive momentum. The RSI at 57.68 is Neutral, neither overbought nor oversold. The STOCH value of 65.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:IPN.
Ipsen Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | €922.44M | 17.31 | 10.49% | 1.06% | -0.95% | 27.67% | |
72 Outperform | €98.71B | 12.92 | 8.39% | 4.77% | -9.82% | 119.10% | |
68 Neutral | €10.56B | 32.73 | 9.69% | 0.82% | 8.28% | -8.08% | |
68 Neutral | €2.92B | 19.88 | 12.62% | 0.41% | 6.97% | -5.59% | |
67 Neutral | €13.04B | 22.37 | 10.82% | 1.17% | 9.57% | -34.30% | |
54 Neutral | €11.31B | 23.65 | 11.27% | 0.97% | 6.25% | 18.93% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
FR:IPN
Ipsen
157.70
52.72
50.22%
FR:BIM
bioMerieux
89.40
-23.96
-21.13%
FR:ERF
Eurofins Scientific
62.08
13.41
27.55%
FR:VETO
VETOQUINOL
78.00
1.42
1.85%
FR:VIRP
Virbac SA
349.00
55.82
19.04%
FR:SAN
Sanofi
81.99
-15.63
-16.01%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.